Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IRF-7 Double Nickase Plasmid (h): sc-400450-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IRF-7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IRF-7 Double Nickase Plasmid (h) and IRF-7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IRF7. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IRF-7 Antibody (F-1): sc-74471
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IRF-7 Double Nickase Plasmid (h) | sc-400450-NIC | 20 µg | $410.00 | |||
IRF-7 Double Nickase Plasmid (h2) | sc-400450-NIC-2 | 20 µg | $410.00 |
Interferon regulatory factor 7 (IRF7) encodes IRF-7, a master transcriptional regulator of type I interferon responses downstream of pattern-recognition receptors such as RIG-I–like receptors and Toll-like receptors. Upon activation by viral nucleic acid sensing, IRF-7 is phosphorylated and translocates to the nucleus to drive expression of IFN-α/β and interferon-stimulated genes, shaping innate antiviral immunity and inflammatory signaling. IRF7 integrates signaling through TBK1/IKKε and cooperates with NF-κB to coordinate cytokine networks that influence immune cell activation and antigen presentation. Dysregulated IRF7 activity has been linked to altered antiviral defense and aberrant interferon signatures observed across immune-mediated disorders and inflammation-associated pathologies, making it a common target for mechanistic studies of interferon pathway control.
IRF-7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IRF7 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IRF7. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IRF7 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IRF7-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.